42 results about "Spin label" patented technology

A magnetic resonance imaging (MRI) method of obtaining MRI images of a patient and storing the images in physical storage media.

Methods of producing and / or analyzing spectroscopically labeled proteins, e.g., proteins site-specifically labeled with NMR active isotopes, spin-labels, chelators for paramagnetic metals, and the like, are provided. The labeled proteins are produced in translation systems including orthogonal aminoacyl tRNA synthetase / tRNA pairs. Methods for assigning NMR resonances, e.g., methods using isotopically labeled proteins, are also provided.

Methods of producing and / or analyzing spectroscopically labeled proteins, e.g., proteins site-specifically labeled with NMR active isotopes, spin-labels, chelators for paramagnetic metals, and the like, are provided. The labeled proteins are produced in translation systems including orthogonal aminoacyl tRNA synthetase / tRNA pairs. Methods for assigning NMR resonances, e.g., methods using isotopically labeled proteins, are also provided.

The present invention relates to a kinase labelled at an amino acid naturally present or introduced in the P-loop of said kinase, wherein said labelling is effected at a free thiol or amino group of said amino acid and said label is (a) a thiol- or amino-reactive fluorophore sensitive to polarity changes in its environment; or (b) a thiol-reactive spin label, an isotope or an isotope-enriched thiol- or amino-reactive label, such that said fluorophore, spin label, isotope or isotope-enriched label does not inhibit the catalytic activity and does not interfere with the stability of the kinase. The invention furthermore relates to a method of screening for kinase inhibitors, a method of determining the kinetics of ligand binding and / or of dissociation of a kinase inhibitor and a method of generating mutated kinases suitable for the screening of kinase inhibitors using the kinase of the present invention.

The invention provides compositions and methods for assessing the capacity of high density lipoprotein (HDL) to support reverse cholesterol transport in blood by measuring exchange if HDL-specific spin-labeled lipoprotein probes and electron paramagnetic spectroscopy. The invention also provides methods to identify individuals at risk for cardiovascular disease, to monitor the treatment of cardiovascular disease and in the development of therapies to treat cardiovascular disease. The invention also provides methods to identify individuals at risk for Alzheimer's disease, to monitor the treatment of Alzheimer's disease and in the development of therapies to treat Alzheimer's disease.

The invention discloses a spin labeled fluorescent probe with single electron structure. The spin labeled fluorescent probe with single electron structure is prepared by the following method: (1) adding rhodamine B and 4-hydroxy-2, 2, 6, 6,-tetramethyl-piperidine nitrogen oxygen free radical into a reaction solvent dichloromethane, adding 4-dimethylaminopyridine to carry out reaction for 20min, then adding N, N'-dicyclohexyl carbodiimide, carrying out reaction at room temperature under argon protection for 24h; and (2) at the end of the reaction, removing the solvent, and subjecting the remaining materials to column chromatography separation: adopting dichloromethane / methanol=20 / 1 (v / v) as the eluant, taking 200-mesh neutral alumina as the stationary phase, collecting eluent, and removing the eluate. The spin labeled fluorescent probe with single electron structure provided by the invention has good cell permeability and low cytotoxicity, can be used for detection of intracellular hydroxyl radicals, mercapto free radicals and, cellular redox environment and oxidation resistance evaluation research of polyphenolic antioxidants.

Spin-labeled ice binding compounds (IBCs) including ice binding proteins (IBPs) or antifreeze proteins (AFPs) and their analogs may carry paramagnetic centers for dynamic nuclear polarization (DNP), for enhancing nuclear magnetic resonance (NMR) signal intensities. Use of spin-labeled IBCs to perform DNP exploits the IBCs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high DNP efficiency. Other advantages of using spin-labeled IBCs include cryo-protecting biological samples; cryo-preserving relative positions and orientations of the spin labeling groups; selecting positions and orientations of spin labeling groups with freedom and without technical barriers to making multiple spin labels in an IBC; and enabling use of a solvent that is primarily water for DNP at low temperatures in view of the potentially high water solubilities of spin-labeled IBCs.

The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

Spin labeled ice binding compounds (IBCs) including ice binding proteins (IBPs), also called antifreeze proteins (AFPs) and their analogs are exploited to carry the paramagnetic centers for dynamic nuclear polarization (DNP), for enhancing nuclear magnetic resonance (NMR) signal intensities. Use of spin labeled IBCs to perform DNP exploits the IBCs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high DNP efficiency. Other advantages of using spin labeled IBCs include: (1) ability to cryo-protect biological samples; (2) the relative positions and orientations of the spin labeling groups in an IBC may also be cryo-preserved; (3) positions and orientations of spin labeling groups to an IBC can be selected with great freedom and without technical barrier to making multiple spin labels in an IBC; and (4) water solubilities of spin labeled IBCs are potentially high, enabling use of a solvent that is primarily water for DNP at low temperatures.

The invention discloses a spin-labeling rotenone oxime ester compound, its preparation method and application. The structural formula of the spin-labeling rotenone oxime ester compound is as show in the formula, wherein the substituent R can be 2,2,5,5-tetramethyl pyrroline nitronyl nitroxide radical, or 2,2,5,5-tetramethyl tetralin pyrroline nitronyl nitroxide radical, or -2,2,6,6-tetramethyl-tetralin pyridine nitronyl nitroxide radical or 2,2,6,6-tetramethyl-piperidine nitronyl nitroxide radical. The spin-labeling rotenone oxime ester compound provided by the invention can be applied in the preparation of antitumor drugs.